Celldex Therapeutics (NASDAQ:CLDX) Hits New 1-Year High – Here’s Why

Posted by George Bondi on Aug 7th, 2026

Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) shares reached a new 52-week high on Wednesday . The company traded as high as $40.30 and last traded at $40.27, with a volume of 220780 shares changing hands. The stock had previously closed at $39.05.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Morgan Stanley raised their price target on Celldex Therapeutics from $40.00 to $46.00 and gave the company an “overweight” rating in a report on Friday. Wall Street Zen raised shares of Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, July 12th. Guggenheim raised their target price on shares of Celldex Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday, July 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Friday, July 17th. Finally, Wells Fargo & Company lifted their target price on shares of Celldex Therapeutics from $48.00 to $72.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $55.46.

Get Our Latest Analysis on Celldex Therapeutics

Celldex Therapeutics Trading Up 0.4%

The stock has a market cap of $3.27 billion, a P/E ratio of -9.79 and a beta of 0.87. The firm has a 50-day simple moving average of $34.99 and a two-hundred day simple moving average of $31.46.

Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.12. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.73 million. Sell-side analysts predict that Celldex Therapeutics, Inc. will post -4.36 earnings per share for the current year.

Institutional Trading of Celldex Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Wellington Management Group LLP raised its holdings in Celldex Therapeutics by 39.3% in the 4th quarter. Wellington Management Group LLP now owns 8,079,608 shares of the biopharmaceutical company’s stock valued at $219,442,000 after acquiring an additional 2,279,605 shares in the last quarter. Vestal Point Capital LP grew its holdings in shares of Celldex Therapeutics by 781.0% during the 2nd quarter. Vestal Point Capital LP now owns 1,750,000 shares of the biopharmaceutical company’s stock worth $35,612,000 after purchasing an additional 1,551,354 shares in the last quarter. Braidwell LP grew its holdings in shares of Celldex Therapeutics by 214.0% during the 4th quarter. Braidwell LP now owns 1,858,109 shares of the biopharmaceutical company’s stock worth $50,466,000 after purchasing an additional 1,266,420 shares in the last quarter. Elmind Capital LP bought a new position in shares of Celldex Therapeutics in the fourth quarter worth $23,493,000. Finally, Assenagon Asset Management S.A. increased its position in shares of Celldex Therapeutics by 438.3% in the second quarter. Assenagon Asset Management S.A. now owns 788,696 shares of the biopharmaceutical company’s stock worth $29,347,000 after purchasing an additional 642,171 shares during the period.

About Celldex Therapeutics

(Get Free Report)

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.